Eyetube Podcasts

In this episode of the Survive & Thrive series, Gary Wörtz, MD, is joined by Nandini Venkateswaran, MD; Dagny Zhu, MD; and guest Preeya Gupta, MD, to talk about one of the big decisions faced by young ophthalmologists: private practice or academia? They weigh the pros and cons of each career path and share their own experiences in navigating this choice.

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year's AAO Annual Meeting Late Breakers session.

NRR's miniseries "The Art of Drug Choice: Wet AMD and the Latest Data" wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.

This NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data" continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?

In episode 2 of the NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data," Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).

No matter how hard you may try to rehabilitate the ocular surface of your dry eye patients, if you don't get good at-home regimens in place, they may fail treatment. In this episode of To the Point, Leslie and Jackie review the three categories of at-home care products available for chronic dry eye: cleansers, heat products, and nutraceuticals. They discuss different examples from each category and offer advice on how to ensure your patients follow their treatment plan.

The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year's AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.

In this podcast episode, Steven J. Dell, MD*, reviews how the addition of the TECNIS® Multifocal Toric II IOL to the TECNIS® II Platform (Johnson & Johnson Vision) compares to the original lenses.

*Steven J. Dell, MD is a paid consultant of Johnson & Johnson Surgical Vision, Inc

Dr. Melissa Barnett and Dr. Tom Arnold talk with guest César Lipener, MD, from São Paulo, Brazil, about his journey of becoming a corneal surgeon and a contact lens specialist. Dr. Lipener shares advice and provides insights on fitting scleral lenses and the potential risks involved.